# GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million

- Link: https://www.thailand-business-news.com/pr-news/gem-and-senhwa-biosciences-have-formally-executed-a-share-purchase-agreement-for-up-to-nt500-million
- Published: 2026-07-15T08:09:00+07:00
- Author: PR Newswire

|   |

TAIPEI and SAN DIEGO, July 15, 2026 /PRNewswire/ — GEM Global Yield LLC SCS ("GEM")
has executed a Share Purchase Agreement (the "SPA") with the existing shareholders
of Taiwan-listed Senhwa Biosciences Inc. (TPEx: 6492), under which GEM has committed
up to NT$500 million (approximately US$15.5 million) to purchase shares in the Company
over the next 3-5 years.

Purchases under the SPA may occur from time to time at the election of certain shareholders,
subject to the terms and conditions of the SPA. During the lifetime of the SPA, 
GEM will not, directly or indirectly, effect any short sale of Senhwa’s shares.

Taiwan’s biotechnology industry continues to attract increasing international attention
through innovative oncology research, expanding global clinical collaborations and
the adoption of artificial intelligence to accelerate drug discovery and clinical
development.

Under the framework of the SPA, the equity commitment from GEM provides additional
financial flexibility and is expected to support continued investment in Senhwa’s
clinical pipeline, potential in-licensing opportunities, and AI-enabled pipeline
prioritization and expansion.

The company’s lead assets are CX-5461 (pidnarulex) and CX-4945 (silmitasertib), 
two investigational oncology therapies being studied across multiple cancer indications.
Senhwa has established research and development collaborations with organizations
including the U.S. National Cancer Institute (NCI), BeOne Medicines, and CellType,
a Y Combinator-backed artificial intelligence company whose platform incorporates
technology developed with Google DeepMind.

"We are very pleased that a prominent international investment group like GEM recognizes
Senhwa’s long-term potential and has chosen to provide access to significant capital
to Senhwa over the next few years," said Dr. Pin-Yen Huang, Acting Chief Executive
Officer of Senhwa Biosciences. "GEM’s validation strengthens our global market positioning
as we continue to advance our oncology pipeline, expand strategic international 
collaborations, and bring innovative therapies to patients around the world."

CX-5461 is currently involved in studies sponsored by the NCI and Senhwa expects
to initiate a clinical study combining the drug with BeOne Medicines’ PD-1 antibody,
tislelizumab. CX-4945 is being investigated across several oncology indications,
including cholangiocarcinoma, CNS tumors and pediatric cancers. In addition, preclinical
studies are evaluating both compounds as potential combination partners for RAS-
targeted therapies, although their clinical utility in this setting has not yet 
been established.

From a regulatory standpoint, both candidates have secured orphan drug and rare 
pediatric disease designations from health authorities. For biotech investors, the
pediatric designation is a key metric, as it preserves the company’s eligibility
to receive a marketable Priority Review Voucher (PRV) should the drugs eventually
secure regulatory approval.

**About GEM**

GEM Global Yield LLC SCS ("GEM") is a $3.4 billion private equity and alternative
investment group with offices in Paris, New York, and Nassau (Bahamas). GEM manages
a diverse set of investment vehicles focused on emerging markets and has completed
over 590 transactions in 70 countries. Its family of funds and investment vehicles
provide GEM and its partners with exposure to small-mid cap management buyouts, 
private investments in public equities, and select venture investments.

**About Senhwa Biosciences**

Senhwa Biosciences Inc. is a Taiwan-based biotechnology company developing novel
oncology therapeutics for cancers with significant unmet medical needs. Its pipeline
includes CX-5461 and CX-4945, which are being evaluated across solid tumors and 
hematologic malignancy indications through international clinical and research collaborations.

**Forward-Looking Statements**

This release contains forward-looking statements regarding, among other things, 
anticipated financing, clinical development plans, regulatory milestones, strategic
collaborations and the potential development of investigational drug candidates.
These statements are subject to risks and uncertainties that could cause actual 
results to differ materially from those expressed or implied, including risks related
to clinical development, regulatory review, financing, commercialization and market
conditions. Nothing contained herein should be construed as a guarantee of future
clinical, regulatory or commercial outcomes.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million ](http://www.prnasia.com/story/archive/5004960_HK04960_0?rand=184833)